Article
Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine.
Clinical and translational science - 1 Apr 2023
Kosloski Matthew P, Li Hong, Wang Stanley, Mensa Federico, Kort Jens, Liu Wei
Abstract excerpt
The fixed-dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once-daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple-dose rifampin study (N = 12) and a carbamazepine study (N = 12) were conducted in healthy subjects to evaluate the effects of CYP3A/P-gp induction and OATP inhibition on the pharmacokinetics of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.